Ter, Higher institute for Analysis and Education in Transfusion Medicine, Tehran, Iran; three Genetic Division, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran; 4Department of Hematology, Faculty of Medicine, Tarbiat Modares University, Tehran, Iransupplemented with ten exosomes-depleted FBS) conditioned by different MSC lines through 48 h. For isolation of exosomes derived from licensed MSCs, harvesting media was supplemented with TNF-, IFN- and IL-1. The overexpression of Hypoxia Inducible Issue (HIF) in MSC was done by lentiviral transduction in the cells. The immunosuppressive capacity of unique MSC lines and the exosomes derived from them was studied by measuring activated T cell proliferation co-cultured with cells or with exosomes for five days. Results: Overexpression of HIF increases immunosuppressive characteristics of MSC. Immunomodulation by MSC is actually a paracrine process and different authors published that exosomes have immunomodulatory capacity. In earlier experiments, we observed that MSC-HIF cells secreted more exosomes than normal MSCs but happen to be able to show now that these exosomes are usually not extra suppressive than their wild form counterparts are. It is actually outstanding that although immunomodulation must be activated in MSCs by pro-inflamatory molecules, exosomes secreted by cIAP-1 Inhibitor Formulation none-licensed MSC already showed regulatory characteristics. Even so, the suppressive capacity of those vesicles is quite restricted and in vivo therapy calls for extremely higher doses of exosomes. In this piece of work, we show that licensing MSC increases the immusuppressive capacity with the exosomes considerably. Summary/Conclusion: Taking all together, we think that a cell-free therapy tactic based on exosomes derived from MSCs could be a protected remedy for autoimmune and inflammatory illnesses Funding: This function was funded by ISCIII [PI16/00107, RD16/0011/ 0004].Background: Microvesicles are capable to induce the cell of origin’s phenotype in a target cell. Leukema is recognized by uncontrolled proliferation of blast cells inside the bone marrow. MicroRNA-21, as an oncomir, is upregulated in nearly all cancer forms including GSK-3 Inhibitor manufacturer leukemia which final results in cell proliferation. In this study, we examine the capacity of leukemia microvesicles to induce hematopoietic stem cells (HSCs) proliferationvia microRNA-21 dysregulation. Solutions: Leukemia microvesicles have been isolated from HL-60 and NB-4 cell lines by ultracentrifuge and then their protein was measured by Bradford process. Regular HSCs have been isolatedfrom umbilical cord blood samples by CD-34 antibody. These cells were treated with 20 and 40 /ml leukemia microvesicles for 5 and 10 days, respectively. Cell count, CD-34 analysis and microRNA-21gene expression assay have been done at day 5 and 10. Outcomes: HSCs showed a important enhance in microRNA-21 gene expression and cell count right after treatingwith leukemia microvesicles comparing with manage groups. CD-34 analysis did not show any difference in studied groups. Summary/Conclusion: This information suggests that HSCs proliferation followed by microRNA-21 gene over expressioncan be another proof of leukemia like phenotype induction within a healthier target cell by leukemia microvesicles.PF03.Stem cell-derived exosomes as a biomaterial source for immune modulating therapy Seulbee Lee1; Hyesun Jung2; Insik Hwang1; Ah-Young Jang1; Kyung-Ah Choi1; Hang-Soo Park1; Sunghoi Hong1 College of Biosystem and Biomedical Science, College of Overall health Science, Korea University, Seoul, Repub.
